Indium In -111 Pentetreotide side effects: what 128 FDA adverse event reports show

Indium In -111 Pentetreotide · Octreoscan · 5 reaction terms · 53 drug–reaction co-reports · data 2026-09-14

Drug class

Agent

FDA label, Indications wording

Brand names

Octreoscan

openFDA label

Who reports

128 reports · 68% serious · 42 with death outcome · 52% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Octreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.

FDA label, Indications and Usage

What it is

DESCRIPTION Octreoscan ™ is a kit for the preparation of Indium In 111 Pentetreotide Injection, a radioactive diagnostic agent. It is a kit consisting of two components: 1) A 10-mL Octreoscan .

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 4 strongest signals

Reporting / coding artifact 1Not in label — unassessed 3

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Intentional drug misuse	31	239.8 176.4–325.9ROR 316.1 · χ² 7,131 / p <1e-300	208.8 EB05 154.1 · IC025 +5.0 3/3 methods agree	Reporting / coding artifact	serious PRR 362.7 · 100% clinician	no trial data cached
Haematotoxicity	7	123.8 60.2–254.4ROR 130.9 · χ² 734 / p 6e-162	93.2 EB05 48.4 · IC025 +2.4 3/3 methods agree	Not in label — unassessed	serious PRR 107.7	no trial data cached
Myelodysplastic syndrome	6	67.9 31.1–148.4ROR 71.2 · χ² 332 / p 2e-74	56.4 EB05 27.7 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 58.1	no trial data cached
Lymphopenia	5	58.2 24.7–137.5ROR 60.6 · χ² 227 / p 1e-51	48.0 EB05 21.8 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 53.3	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Intentional drug misuse	31	239.8 176.4–325.9ROR 316.1 · χ² 7,131 / p <1e-300	208.8 EB05 154.1 · IC025 +5.0 3/3 methods agree	Reporting / coding artifact	serious PRR 362.7 · 100% clinician	no trial data cached
Haematotoxicity	7	123.8 60.2–254.4ROR 130.9 · χ² 734 / p 6e-162	93.2 EB05 48.4 · IC025 +2.4 3/3 methods agree	Not in label — unassessed	serious PRR 107.7	no trial data cached
Myelodysplastic syndrome	6	67.9 31.1–148.4ROR 71.2 · χ² 332 / p 2e-74	56.4 EB05 27.7 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	serious PRR 58.1	no trial data cached
Lymphopenia	5	58.2 24.7–137.5ROR 60.6 · χ² 227 / p 1e-51	48.0 EB05 21.8 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 53.3	no trial data cached
Acute myeloid leukaemia	4	42.1 16.0–110.4ROR 43.4 · χ² 122 / p 1e-28	33.9 EB05 11.8 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 35.8	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Indium In -111 Pentetreotide?

In FDA FAERS, the most frequently co-reported reaction terms for Indium In -111 Pentetreotide are haematotoxicity, myelodysplastic syndrome, lymphopenia, acute myeloid leukaemia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Indium In -111 Pentetreotide have an FDA boxed warning?

No. The FDA label retrieved for Indium In -111 Pentetreotide has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Indium In -111 Pentetreotide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 93d8f3b2-1216-41dc-a63d-0e812b33891d, effective 20220221; matched on openfda.generic_name.exact:"INDIUM IN -111 PENTETREOTIDE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 5 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.